Page last updated: 2024-12-07
thiazopyr
Description
Thiazopyr is a synthetic herbicide belonging to the pyrazole group. Its primary mode of action is through inhibiting the synthesis of protoporphyrin IX, a crucial molecule in chlorophyll production. This disruption disrupts photosynthesis and leads to plant death. Thiazopyr is effective in controlling a wide range of weeds, particularly grasses, in crops such as soybeans, peanuts, and cotton. It is commonly used as a pre-emergence herbicide, applied before the weeds germinate. Research on thiazopyr focuses on understanding its environmental fate, its impact on non-target organisms, and developing more efficient and sustainable applications. Notably, thiazopyr's selectivity for specific weeds and its relatively low persistence in soil make it a valuable tool for weed management. However, continued research is essential to ensure its responsible and safe use.'
thiazopyr: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 91776 |
CHEMBL ID | 1886222 |
CHEBI ID | 166573 |
SCHEMBL ID | 53467 |
MeSH ID | M0242220 |
Synonyms (36)
Synonym |
CHEBI:166573 |
methyl 2-(diluoromethyl)-5-(4,5-dihydro-1,3-thiazol-2-yl)-4-(2-methylpropyl)-6-(triluoromethyl)pyridine-3-carboxylate |
mon 13200 |
thiazophyr |
thiazopyr [iso] |
mon 13211 |
3-pyridinecarboxylic acid, 2-(difluoromethyl)-5-(4,5-dihydro-2-thiazolyl)-4-(2-methylpropyl)-6-(trifluoromethyl)-, methyl ester |
visor |
mandate |
hsdb 7015 |
methyl 2-(difluoromethyl)-5-(4,5-dihydro-2-thiazolyl)-4-(2-methylpropyl)-6-(trifluoromethyl)-3-pyridinecarboxylate |
NCGC00163867-01 |
thiazopyr |
methyl 2-(difluoromethyl)-5-(4,5-dihydro-1,3-thiazol-2-yl)-4-isobutyl-6-(trifluoromethyl)nicotinate |
117718-60-2 |
NCGC00163867-02 |
methyl 2-(difluoromethyl)-5-(4,5-dihydro-1,3-thiazol-2-yl)-4-(2-methylpropyl)-6-(trifluoromethyl)pyridine-3-carboxylate |
NCGC00163867-03 |
tox21_300822 |
cas-117718-60-2 |
dtxsid1032488 , |
NCGC00254726-01 |
dtxcid9012488 |
147172-37-0 |
aeq9r142xi , |
unii-aeq9r142xi |
FT-0631089 |
AKOS015890794 |
SCHEMBL53467 |
thiazopyr [mi] |
thiazopyr [hsdb] |
methyl 2-difluoromethyl-5-(4,5-dihydro-1,3-thiazol-2-yl)-4-isobutyl-6-trifluoromethylnicotinate |
CHEMBL1886222 |
methyl 2-(difluoromethyl)-5-(4,5-dihydrothiazol-2-yl)-4-isobutyl-6-(trifluoromethyl)nicotinate |
Q22808964 |
methyl 2-(difluoromethyl)-5-(4,5-dihydro-1,3-thiazol-2-yl)-4-(2-methyl propyl)-6-(trifluoromethyl)py |
Drug Classes (2)
Class | Description |
aromatic carboxylic acid | Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring. |
pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (9)
Potency Measurements
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.85
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 22.85 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.21 (4.65) | Search Engine Demand Index | 21.17 (26.88) | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |